2-Hexanone

CASRN 591-78-6

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (19 pp, 148 K) last updated: 09/25/2009

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
5 x 10-3 Nervous Axonal swelling of the peripheral nerve BMDL10 : 5
mg/kg-day
1000 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (19 pp, 148 K) last updated: 09/25/2009

RfC (mg/m3) System Basis PoD Composite UF Confidence
3 x 10-2 Nervous Motor conduction velocity of the sciatic-tibial nerve BMCL05 (HEC): 90
mg/m3
3000 Low

Cancer Assessment


Weight of Evidence for Cancer (PDF) (19 pp, 148 K) last updated: 09/25/2009

WOE Characterization Framework for WOE Characterization
Inadequate information to assess carcinogenic potential Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for 2-hexanone is "inadequate to assess human carcinogenic potential."
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (19 pp, 148 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (19 pp, 148 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.